MaxCyte Inc. (MXCT) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, MXCT scores 35 out of 100 (letter grade D-, verdict "Roarable Sell — Vulnerable Balance Sheet & Flow"). The five pillars are:

• Fundamental cash engine (4 / 20): The rating cites ROIC of -27.1% and an FCF yield of -20.26%. Operating margin and net margin are both -60%, so the business is currently consuming cash rather than generating it. For a prospective investor, the upside case depends on a turn in operating economics that the current figures do not show.
• Whale 13F flow (15 / 20): This is the strongest pillar, reflecting institutional accumulation and options positioning. Institutional interest is a partial offset to the weak fundamentals, though it does not change the cash-flow picture.
• Insider conviction (3 / 20): The rating reflects SEC Form 4 and Congressional PTR cluster flow scored weakly. Insider signals provide limited support for the thesis.
• Macro regime fit (8 / 20): Beta of 1.0 and the sector-sensitivity assessment place MXCT in a moderate-to-weak position relative to macro conditions.
• Forensic balance sheet (5 / 20): Per the rating, Altman Z is 1.52, Piotroski F is 3/9, and Debt/Equity is 0.5. These point to a stretched financial position with limited margin for error.

Taken together, the investor implication is that the stock's low price ($1.73) and its institutional interest are offset by negative cash generation, weak forensic scores, and sub-par insider signals. Valuation tradeoffs are difficult to assess because P/E and EPS are not available in source data, so the investment case cannot be anchored to earnings. This brief is educational and not personalized financial advice.

Per the SEC financials, revenue moved from $19.5M to $22.2M and then to $21.0M across the three reported years, while operating losses widened from $-48.3M to $-51.9M. Per the market data, gross margin is 96%, while operating and net margins are both -60%, and ROIC is -27.1%. Altman Z-Score is 1.52 and Piotroski F-Score is 3/9 per the Roarable RQD rating. Cash declined from $27.9M to $20.1M over the last two reported years, and debt is reported as N/A in the financials, with Debt/Equity of 0.5 per the rating.

• Catalyst (GREEN): A report on MaxCyte hiring a Danaher dealmaker to drive growth, which is the only item flagged as a catalyst rather than general market wire.
• Institutional activity (YELLOW): A Stock Titan report of an investor disclosing over 5% of MXCT after October 14 share purchases.
• Market wire (YELLOW): Several items covering intraday moves, options-chain quotes, and a euro-denominated quote near EUR 1.53 on October 29.
• Proprietary signals: Not available in source data (the Butterfly graph lists none).
• Risk watch: The news flow is largely market-activity reporting; the sustainability of the revenue and loss trends is not addressed in the headlines.

• What are the revenue drivers behind the $19.5M to $22.2M to $21.0M trajectory, and is there a path to positive operating income?
• What is the debt structure, given that debt is reported as N/A while Debt/Equity is 0.5?
• What is the identity and cash-runway position implied by $20.1M of cash against $-36.2M of FCF?
• What is the forward earnings or EBITDA expectation, given that P/E, EV/EBITDA, and EPS are all unavailable?
• What do the 13F and Form 4 filings show in detail beyond the single >5% holder headline?